Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TolDCB29 tolerogenic dendritic cell therapy for rheumatoid arthritis
NL-OMON55219Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Aug 2021
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Open-label trial of TolDCB29 in rheumatoid arthritis (RA), sponsored by University Medical Center Utrecht. Primary endpoint: Safety. Started Aug 2021; status: recruiting.
02
Drugs
TolDCB29
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON55219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55219.